Scarfò Lydia Ricercatore a tempo determinato juniorMedicineMED/09




Degree in Medicine and Surgery at the University of Ferrara in 2006, Specialization in Hematology in 2012, Specialization in Internal Medicine in 2017. In 2012 she moved to the San Raffaele Scientific Institute, Milano, where she is now involved in both preclinical and clinical studies. She is currently co-investigator in over 20 clinical trials in CLL and related disorders, including phase 1 studies; she is principal investigator in a Phase 3 trial for first-line treatment in follicular lymphoma. She successfully completed the Clinical Research Training in Hematology (CRTH) year 2016-2017, promoted by the European Hematology Association (EHA).

Fields of research

  • prognostic and predictive factors in chronic lymphocytic leukemia (CLL)
  • pre-neoplastic conditions associated with B-cell lymphoproliferative disorders, e.g. monoclonal B-cell lymphocytosis (MBL)
  • targeted agents and clinical trial design


Minici C, Gounari M, Übelhart R, Scarfò L, Dühren-von Minden M, Schneider D, Tasdogan A, Alkhatib A, Agathangelidis A, Ntoufa S, Chiorazzi N, Jumaa H, Stamatopoulos K, Ghia P, Degano M. Distinct homotypic B-cell receptor interactions shape the outcome of chronic lymphocytic leukaemia.

Nat Commun. 2017 Jun 9;8:15746.


Xochelli A, Baliakas P, Kavakiotis I, Agathangelidis A, Sutton LA, Minga E, Ntoufa S, Tausch E, Yan XJ, Shanafelt TD, Plevova K, Boudjogra M, Rossi D, Davis Z, Navarro A, Sandberg Y, Vojdeman FJ, Scarfò L, Stavroyianni N, Sudarikov A, Veronese S, Tzenou T, Karan Djurasevic T, Catherwood MA, Kienle D, Chatzouli M, Facco M, Bahlo J, Pott C, Pedersen LB, Mansouri L, Smedby KE, Chu CC, Giudicelli V, Lefranc MP, Panagiotidis P, Juliusson G, Anagnostopoulos A, Vlahavas I, Antic D, Trentin L, Montillo M, Niemann CU, Dohner H, Langerak AW, Pospisilova S, Hallek M, Campo E, Chiorazzi N, Maglaveras N, Oscier D, Gaidano G, Jelinek DF, Stilgenbauer S, Chouvarda I, Darzentas N, Belessi C, Davi F, Hadzidimitriou A, Rosenquist R, Ghia P, Stamatopoulos K. CHRONIC LYMPHOCYTIC LEUKEMIA WITH MUTATED IGHV4-34 RECEPTORS: SHARED AND DISTINCT IMMUNOGENETIC FEATURES AND CLINICAL OUTCOMES.

Clin Cancer Res. 2017 May 23. pii: clincanres.3100.2016. doi: 10.1158/1078-0432.CCR-16-3100. [Epub ahead of print]


Gorini F, Azzimonti L, Delfanti G, Scarfò L, Scielzo C, Bertilaccio MT, Ranghetti P, Gulino A, Doglioni C, Di Napoli A, Capri M, Franceschi C, Caligaris-Cappio F, Ghia P, Bellone M, Dellabona P, Casorati G, de Lalla C. Invariant NKT cells contribute to chronic lymphocytic leukemia surveillance and prognosis.

Blood. 2017 Jun 29;129(26):3440-3451.


Vilia MG, Fonte E, Veliz Rodriguez T, Tocchetti M, Ranghetti P, Scarfò L, Papakonstantinou N, Ntoufa S, Stamatopoulos K, Ghia P, Muzio M.The inhibitory receptor toll interleukin-1R 8 (TIR8/IL-1R8/SIGIRR) is downregulated in chronic lymphocytic leukemia.

Leuk Lymphoma. 2017 Oct;58(10):2419-2425.


Ferreri AJ, Sassone M, Zaja F, Re A, Spina M, Rocco AD, Fabbri A, Stelitano C, Frezzato M, Rusconi C, Zambello R, Couto S, Ren Y, Arcari A, Bertoldero G, Nonis A, Scarfò L, Calimeri T, Cecchetti C, Chiozzotto M, Govi S, Ponzoni M. Lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplantation: an open label, single-arm, multicentre phase 2 trial.

Lancet Haematol. 2017 Mar;4(3):e137-e146.


Ghia P, Scarfò L*, Perez S, Pathiraja K, Derosier M, Small K, Sisk CM, Patton N. Efficacy and safety of dinaciclib versus ofatumumab in patients with relapsed/refractory chronic lymphocytic leukemia. *shared first authorship

Blood. 2017 Jan 26. pii: blood-2016-10-748210.


McMahon KM, Scielzo C, Angeloni NL, Deiss-Yehiely E, Scarfo L, Ranghetti P, Ma S, Kaplan J, Barbaglio F, Gordon LI, Giles FJ, Thaxton CS, Ghia P. Synthetic high-density lipoproteins as targeted monotherapy for chronic lymphocytic leukemia.

Oncotarget. 2017 Jan 4. doi: 10.18632/oncotarget.14494.


Scarfò L, Ferreri AJ, Ghia P. Chronic lymphocytic leukaemia.

Crit Rev Oncol Hematol. 2016 Aug;104:169-82.


Scarfò L, Ghia P. What does it mean I have a monoclonal B-cell lymphocytosis?: Recent insights and new challenges.

Semin Oncol. 2016;43(2):201-8.


Bianco M, Gasparri A, Generoso L, Assi E, Colombo B, Scarfò L, Bertilaccio MT, Scielzo C, Ranghetti P, Dondossola E, Ponzoni M, Caligaris-Cappio F, Ghia P, Corti A. Inhibition of chronic lymphocytic leukemia progression by full-length chromogranin A and its N-terminal fragment in mouse models.

Oncotarget. 2016;7(27):41725-41736.


Sutton LA, Young E, Baliakas P, Hadzidimitriou A, Moysiadis T, Plevova K, Rossi D, Kminkova J, Stalika E, Pedersen LB, Malcikova J, Agathangelidis A, Davis Z, Mansouri L, Scarfò L, Boudjoghra M, Navarro A, Muggen AF, Yan XJ, Nguyen-Khac F, Larrayoz M, Panagiotidis P, Chiorazzi N, Niemann CU, Belessi C, Campo E, Strefford JC, Langerak AW, Oscier D, Gaidano G, Pospisilova S, Davi F, Ghia P, Stamatopoulos K, Rosenquist R; ERIC, the European Research Initiative on CLL. Different spectra of recurrent gene mutations in subsets of chronic lymphocytic leukemia harboring stereotyped B-cell receptors.

Haematologica 2016;101(8):959-67.


Galletti G, Scielzo C, Barbaglio F, Rodriguez TV, Riba M, Lazarevic D, Cittaro D, Simonetti G, Ranghetti P, Scarfò L, Ponzoni M, Rocchi M, Corti A, Anselmo A, van Rooijen N, Klein C, Ries CH, Ghia P, De Palma M, Caligaris-Cappio F, Bertilaccio MT. Targeting Macrophages Sensitizes Chronic Lymphocytic Leukemia to Apoptosis and Inhibits Disease Progression.

Cell Rep. 2016;14(7):1748-60.


Valsecchi R, Coltella N, Belloni D, Ponente M, Ten Hacken E, Scielzo C, Scarfò L, Bertilaccio MT, Brambilla P, Lenti E, Martinelli Boneschi F, Brendolan A, Ferrero E, Ferrarini M, Ghia P, Tonon G, Ponzoni M, Caligaris-Cappio F, Bernardi R. HIF-1α regulates the interaction of chronic lymphocytic leukemia cells with the tumor microenvironment.

Blood. 2016;127(16):1987-97.


Fonte E, Agathangelidis A, Reverberi D, Ntoufa S, Scarfò L, Ranghetti P, Cutrona G, Tedeschi A, Xochelli A, Caligaris-Cappio F, Ponzoni M, Belessi C, Davis Z, Piris MA, Oscier D, Ghia P, Stamatopoulos K, Muzio M. Toll-Like receptor stimulation in splenic marginal zone lymphoma can modulate cell signaling, activation and proliferation.

Haematologica. 2015 Nov;100(11):1460-8.


Tedeschi A, Rossi D, Motta M, Quaresmini G, Rossi M, Coscia M, Anastasia A, Rossini F, Cortelezzi A, Nador G, Scarfò L, Cairoli R, Frustaci AM, Dalceggio D, Picardi P, De Paoli L, Orlandi E, Rambaldi A, Massaia M, Gaidano G, Montillo M; Rete Ematologica Lombarda–CLL Workgroup. A phase II multi-center trial of pentostatin plus cyclophosphamide with ofatumumab in older previously untreated chronic lymphocytic leukemia patients.

Haematologica. 2015 Dec;100(12):e501-4.


Baliakas P, Hadzidimitriou A, Agathangelidis A, Rossi D, Sutton LA, Kminkova J, Scarfo L, Pospisilova S, Gaidano G, Stamatopoulos K, Ghia P, Rosenquist R. Prognostic relevance of MYD88 mutations in CLL: the jury is still out.

Blood 2015 Aug 20;126(8):1043-4


Agathangelidis A, Scarfò L, Barbaglio F, Apollonio B, Bertilaccio MT, Ranghetti P, Ponzoni M, Leone G, De Pascali V, Pecciarini L, Ghia P, Caligaris-Cappio F, Scielzo C. Establishment and Characterization of PCL12, a Novel CD5+ Chronic Lymphocytic Leukaemia Cell Line.

PLoS One. 015 Jun 25;10(6):e0130195


Ferreri AJ, Sassone M, Kiesewetter B, Govi S, Scarfò L, Donadoni G, Raderer M. High-dose clarithromycin is an active monotherapy for patients with relapsed/refractory extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT): the HD-K phase II trial.

Ann Oncol. 2015;26(8):1760-5.


Baliakas P, Agathangelidis A, Hadzidimitriou A, Sutton LA, Minga E, Tsanousa A, Scarfò L, Davis Z, Yan XJ, Shanafelt T, Plevova K, Sandberg Y, Vojdeman FJ, Boudjogra M, Tzenou T, Chatzouli M, Chu CC, Veronese S, Gardiner A, Mansouri L, Smedby KE, Pedersen LB, Moreno D, Van Lom K, Giudicelli V, Francova HS, Nguyen-Khac F, Panagiotidis P, Juliusson G, Angelis L, Anagnostopoulos A, Lefranc MP, Facco M, Trentin L, Catherwood M, Montillo M, Geisler CH, Langerak AW, Pospisilova S, Chiorazzi N, Oscier D, Jelinek DF, Darzentas N, Belessi C, Davi F, Ghia P, Rosenquist R, Stamatopoulos K. Not all IGHV3-21 chronic lymphocytic leukemias are equal: prognostic considerations.

Blood. 2015 Jan 29;125(5):856-9


Baliakas P, Hadzidimitriou A, Sutton LA, Minga E, Agathangelidis A, Nichelatti M, Tsanousa A, Scarfò L, Davis Z, Yan XJ, Shanafelt T, Plevova K, Sandberg Y, Vojdeman FJ, Boudjogra M, Tzenou T, Chatzouli M, Chu CC, Veronese S, Gardiner A, Mansouri L, Smedby KE, Bredo Pedersen L, van Lom K, Giudicelli V, Skuhrova Francova H, Nguyen-Khac F, Panagiotidis P, Juliusson G, Angelis L, Anagnostopoulos A, Lefranc MP, Facco M, Trentin L, Catherwood M, Montillo M, Geisler CH, Langerak AW, Pospisilova S, Chiorazzi N, Oscier D, Jelinek DF, Darzentas N, Belessi C, Davi F, Rosenquist R, Ghia P, Stamatopoulos K.  Clinical effect of stereotyped B-cell receptor immunoglobulins in chronic lymphocytic leukaemia: a retrospective multicentre study.

Lancet Haematology, 2014; 1: e74–84


Ferreri AJ, Bruno-Ventre M, Donadoni G, Ponzoni M, Citterio G, Foppoli M, Vignati A, Scarfò L, Sassone M, Govi S, Caligaris-Cappio F. Risk-tailored CNS prophylaxis in a mono-institutional series of 200 patients with diffuse large B-cell lymphoma treated in the rituximab era.

Br J Haematol. 2015 Mar;168(5):654-62


Baliakas P, Hadzidimitriou A, Sutton LA, Rossi D, Minga E, Villamor N, Larrayoz M, Kminkova J, Agathangelidis A, Davis Z, Tausch E, Stalika E, Kantorova B, Mansouri L, Scarfò L, Cortese D, Navrkalova V, Rose-Zerilli MJ, Smedby KE, Juliusson G, Anagnostopoulos A, Makris AM, Navarro A, Delgado J, Oscier D, Belessi C, Stilgenbauer S, Ghia P, Pospisilova S, Gaidano G, Campo E, Strefford JC, Stamatopoulos K, Rosenquist R, European Research Initiative on CLL (ERIC). Recurrent mutations refine prognosis in chronic lymphocytic leukemia.

Leukemia. 2015 Feb;29(2):329-36


Malcikova J, Stalika E, Davis Z, Plevova K, Trbusek M, Mansouri L, Scarfò L, Baliakas P, Gardiner A, Sutton LA, Francova HS, Agathangelidis A, Anagnostopoulos A, Tracy I, Makris A, Smardova J, Ghia P, Belessi C, Gonzalez D, Rosenquist R, Oscier D, Pospisilova S, Stamatopoulos K. The frequency of TP53 gene defects differs between chronic lymphocytic leukaemia subgroups harbouring distinct antigen receptors.

Br J Haematol. 2014 Aug;166(4):621-5.


Bruno Ventre M, Ferreri AJ, Gospodarowicz M, Govi S, Messina C, Porter D, Radford J, Heo DS, Park Y, Martinelli G, Taylor E, Lucraft H, Hong A, Scarfò L, Zucca E, Christie D; International Extranodal Lymphoma Study Group. Clinical features, management, and prognosis of an international series of 161 patients with limited-stage diffuse large B-cell lymphoma of the bone (the IELSG-14 study).

Oncologist. 2014 Mar;19(3):291-8.


Messina C, Ferreri AJ, Govi S, Bruno-Ventre M, Gracia Medina EA, Porter D, Radford J, Heo DS, Park HY, Pro B, Jayamohan J, Visco C, Scarfò L, Zucca E, Gospodarowicz M, Christie D; International Extranodal Lymphoma Study Group (I.E.L.S.G.). Clinical features, management and prognosis of multifocal primary bone lymphoma: a retrospective study of the international extranodal lymphoma study group (the IELSG 14 study).

Br J Haematol. 2014 Mar;164(6):834-40.


Vardi A, Agathangelidis A, Sutton LA, Chatzouli M, Scarfo L, Mansouri L, Douka V, Anagnostopoulos A, Darzentas N, Rosenquist R, Ghia P, Belessi C, Stamatopoulos K. IgG-switched CLL has a distinct immunogenetic signature from the common MD variant: ontogenetic implications.

Clin Cancer Res. 2014;20:323-330   doi: 10.1158/1078-0432

Scarfò L, Ghia P. Reprogramming cell death: bcl2 family inhibition in hematological malignancies.

Immunol Lett. 2013;155:36-39


Karube K, Scarfò L*, Campo E, Ghia P. Monoclonal B cell lymphocytosis and “in situ” lymphoma. *shared first authorship

Semin Cancer Biol. 2014 Feb;24:3-14.


Vardi A, Dagklis A, Scarfò L, Jelinek D, Newton D, Bennett F, Almeida J, Rodriguez-Caballero A, Allgood S, Lanasa M, Cortelezzi A, Orlandi E, Veronese S, Montillo M, Rawstron A, Shanafelt T, Orfao A, Stamatopoulos K, Ghia P. Immunogenetics shows that not all MBL are equal: the larger the clone the more similar to CLL.

Blood. 2013;121:4521-4528


Scarfò L, Fazi C, Ghia P. MBL Versus CLL: How Important Is the Distinction?

Hematol Oncol Clin North Am. 2013;27:251-265


Strefford JC, Sutton LA, Baliakas P, Agathangelidis A, Malčíková J, Plevova K, Scarfó L, Davis Z, Stalika E, Cortese D, Cahill N, Pedersen LB, di Celle PF, Tzenou T, Geisler C, Panagiotidis P, Langerak AW, Chiorazzi N, Pospisilova S, Oscier D, Davi F, Belessi C, Mansouri L, Ghia P, Stamatopoulos K, Rosenquist R. Distinct patterns of novel gene mutations in poor-prognostic stereotyped subsets of chronic lymphocytic leukemia: the case of SF3B1 and subset #2.

Leukemia. 2013 Nov;27(11):2196-9


Apollonio B, Scielzo C, Bertilaccio MT, Ten Hacken E, Scarfò L, Ranghetti P, Stevenson F, Packham G, Ghia P, Muzio M, Caligaris-Cappio F. Targeting B cell anergy in chronic lymphocytic leukemia.

Blood. 2013 May 9;121(19):3879-88


Ten Hacken E, Scielzo C, Bertilaccio MT, Scarfò L, Apollonio B, Barbaglio F, Stamatopoulos K, Ponzoni M, Ghia P, Caligaris-Cappio F. Targeting the LYN/HS1 signaling axis in chronic lymphocytic leukemia.

Blood. 2013 Mar 21;121(12):2264-73.


Fonte E, Apollonio B, Scarfò L, Ranghetti P, Fazi C, Ghia P, Caligaris-Cappio F, Muzio M. In Vitro Sensitivity of CLL Cells to Fludarabine May Be Modulated by the Stimulation of Toll-like Receptors.

Clin Cancer Res. 2013;19:367-379


Ponzoni M, Kanellis G, Pouliou E, Baliakas P, Scarfò L, Ferreri AJ, Doglioni C, Bikos V, Dagklis A, Anagnostopoulos A, Ghia P, Stamatopoulos K, Papadaki T. Bone Marrow Histopathology in the Diagnostic Evaluation of Splenic Marginal-zone and Splenic Diffuse Red Pulp Small B-cell Lymphoma: A Reliable Substitute for Spleen Histopathology?

Am J Surg Pathol. 2012;36:1609-1618


Scarfò L, Zibellini S, Tedeschi A, Maura F, Neri A, Bertazzoni P, Sarina B, Nalli G, Motta M, Rossini F, Cortelezzi A, Montillo M, Orlandi E, Ghia P. Impact of B-cell count and imaging screening in cMBL: any need to revise the current guidelines?

Leukemia. 2012;26:1703-1707


Fazi C, Scarfò L*, Pecciarini L, Cottini F, Dagklis A, Janus A, Talarico A, Scielzo C, Sala C, Toniolo D, Caligaris-Cappio F, Ghia P. General population low-count CLL-like MBL persist over time without clinical progression, though carrying the same cytogenetic abnormalities of CLL. *Shared first authorship

Blood. 2011;118:6618-6625


Scielzo C, Apollonio B, Scarfò L, Janus A, Muzio M, Ten Hacken E, Ghia P, Caligaris-Cappio F. The functional in vitro response to CD40 ligation reflects a different clinical outcome in patients with chronic lymphocytic leukemia.

Leukemia. 2011;25:1760-1767


Fazi C, Dagklis A, Cottini F, Scarfò L, Bertilaccio MT, Finazzi R, Memoli M, Ghia P. Monoclonal B cell lymphocytosis in hepatitis C virus infected individuals.

Cytometry B Clin Cytom. 2010;78 Suppl 1:S61-68


Scarfò L, Dagklis A, Scielzo C, Fazi C, Ghia P. CLL-like monoclonal B-cell lymphocytosis: are we all bound to have it?

Semin Cancer Biol. 2010;20:384-390


Frenquelli M, Muzio M, Scielzo C, Fazi C, Scarfò L, Rossi C, Ferrari G, Ghia P, Caligaris-Cappio F. MicroRNA and proliferation control in chronic lymphocytic leukemia: functional relationship between miR-221/222 cluster and p27.

Blood. 2010;115:3949-3959


Bertilaccio MT, Scielzo C, Simonetti G, Ponzoni M, Apollonio B, Fazi C, Scarfò L, Rocchi M, Muzio M, Caligaris-Cappio F, Ghia P. A novel Rag2-/-gammac-/–xenograft model of human CLL.

Blood. 2010;115:1605-1609


Dagklis A, Fazi C, Scarfo L, Apollonio B, Ghia P. Monoclonal B lymphocytosis in the general population.

Leuk Lymphoma. 2009;50:490-2

Il titolare del presente curriculum vitae, pubblicato online sul portale, è garante in via esclusiva della correttezza e della veridicità dei dati e delle informazioni in esso riportate e del loro eventuale e puntuale aggiornamento. Egli è dunque il diretto ed unico responsabile dei contenuti indicati nei propri curricula.